Hennion & Walsh Asset Management Inc. Has $3.95 Million Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Hennion & Walsh Asset Management Inc. grew its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 1.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 199,525 shares of the company’s stock after buying an additional 3,673 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Kiniksa Pharmaceuticals were worth $3,947,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in KNSA. Essex Investment Management Co. LLC boosted its stake in Kiniksa Pharmaceuticals by 0.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 200,516 shares of the company’s stock worth $5,011,000 after acquiring an additional 717 shares during the last quarter. Franklin Resources Inc. increased its stake in Kiniksa Pharmaceuticals by 1.7% in the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock valued at $1,798,000 after purchasing an additional 1,100 shares in the last quarter. CWM LLC raised its holdings in Kiniksa Pharmaceuticals by 443.0% in the third quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the period. Quarry LP bought a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth $50,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Kiniksa Pharmaceuticals by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock valued at $195,000 after buying an additional 3,076 shares during the period. 53.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on KNSA. Evercore ISI raised their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Wedbush restated an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Monday. Finally, JPMorgan Chase & Co. lifted their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $36.60.

Kiniksa Pharmaceuticals Trading Down 2.3 %

KNSA opened at $18.39 on Friday. The stock has a market capitalization of $1.33 billion, a P/E ratio of -131.35 and a beta of 0.29. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $16.56 and a 12 month high of $28.15. The firm’s fifty day simple moving average is $20.76 and its 200 day simple moving average is $23.21.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The firm had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business’s revenue for the quarter was up 67.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.20) earnings per share. On average, equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the sale, the chief operating officer now directly owns 88,975 shares in the company, valued at $1,622,904. This trade represents a 13.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at approximately $492,449.10. This represents a 28.09 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,092 shares of company stock worth $471,609. Corporate insiders own 54.57% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.